Evidence map›Paper›PMID 38502398›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2024

Four-Color ImmunoSpot

Lingling Yao, Noémi Becza, Andrea Maul-Pavicic, Jack Chepke, Greg A Kirchenbaum, Paul V Lehmann

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Extending ImmunoSpotVaccines · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lingling YaoResearch & Development Department, Cellular Technology Limited, Shaker Heights, OH, USA.
Noémi BeczaResearch & Development Department, Cellular Technology Limited, Shaker Heights, OH, USA.
Andrea Maul-PavicicResearch & Development Department, Cellular Technology Limited, Shaker Heights, OH, USA.
Jack ChepkeResearch & Development Department, Cellular Technology Limited, Shaker Heights, OH, USA.
Greg A KirchenbaumResearch & Development Department, Cellular Technology Limited, Shaker Heights, OH, USA. greg.kirchenbaum@immunospot.com.
Paul V LehmannResearch & Development Department, Cellular Technology Limited, Shaker Heights, OH, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The B lymphocyte response can encompass four immunoglobulin (Ig) classes and four IgG subclasses, each contributing fundamentally different effector functions. Production of the appropriate Ig class/subclass is critical for both successful host defense and avoidance of immunopathology. The assessment of an antigen-specific B cell response, including its magnitude and Ig class/subclass composition, is most often confined to the antibodies present in serum and other biological fluids and neglects monitoring of the memory B cell (B

Indexed as

B-LymphocytesLeukocytes, MononuclearAntibody-Producing CellsAntigensImmunoglobulin GImmunoglobulinsAntigensImmunoglobulin GImmunoglobulinsAntibody-secreting cellB cellsELISPOTFluoroSpotHigh throughputIg classIgG subclassImmune memoryImmune monitoring

Identifiers

PMID38502398

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.